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Received August 3, 2012; accepted March 28, 2013AbstractBackground: Few studies have evaluated the effects and precise molecular mechanism of mycophenolate mofetil (MMF) in the treatment of
human cutaneous lupus erythematosus (CLE). Our findings shed light on the therapeutic effects of MMF in a UVB-induced NZB  NZW
(NZBW) F1 CLE mouse model.
Methods: Continuous MMF treatment (60 mg/kg/day) was administered up to Day 50 from the beginning of UVB induction (Day 0; 20 weeks
old), as the pathologic features of CLE are present after 50 days. The therapeutic effects of MMF treatment in NZBW lupus mice were examined
by comparing histopathological changes, lupus band test (deposition of immune complexes at the dermaleepidermal junction) and colocali-
zation of autoantibodies with a dermal autoantigen Dsg3, and by evaluating the associations of local matrix metalloprotease activities.
Results: MMF improved survival in the NZBW lupus mice from 35.7% to 81.8%. The proteinuria, blood urea nitrogen, and interleukin 6 levels
were significantly reduced after MMF treatment. The dermal lymphocytic infiltration, deposition of immune complexes at the dermaleepidermal
junction, colocalized autoantibodies with Dsg3, and epidermal matrix metalloprotease activity were also attenuated in MMF-treated NZBW F1
mice.
Conclusion: The results confirmed that MMF could substantially attenuate skin damage due to CLE in the NZBW F1 mouse model.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Lupus erythematosus (LE) includes a disease group that
may involve one or many organ systems. Skin involvement is a
major feature of LE in 70e85% of patients with systemic LE.
Cutaneous LE (CLE) includes subacute CLE, LE tumidus and
discoid LE. Of these, the most photosensitive are subacute
CLE and LE tumidus. The anti-Ro/SSA antibody is strongly
correlated with subacute CLE but rarely present in discoid LE* Corresponding author. Dr. Yung-Tsung Chiu, Department of Medical Ed-
ucation and Research, Taichung Veterans General Hospital, 160, Section 3,
Chung-Kang Road, Taichung 407, Taiwan, ROC.
E-mail address: ytchiu@vghtc.gov.tw (Y.-T. Chiu).
1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.07.010or LE tumidus.1,2 Ultraviolet (UV) light (UVA, UVB), and
visible light can provoke lesions in all photosensitive forms of
CLE.3e5 These dermatological manifestations are well-
described and are typically characterized by extensive depo-
sition of immunoglobulin G (IgG), IgM, and IgA, as well as
complements C3 and C1q. Dermal MMP-2 and MMP-9 with
gelatinase activity can degrade extracellular matrix, making
them accessible for the deposition of immune complexes and
promoting progression of the disease in the skin of lupus-
prone mice.6
Mycophenolate mofetil (MMF), an inhibitor of inosine
monophosphate dehydrogenase (IMPDH), acts as a selective
and potent immunosuppressive agent and affects the gonadal
organs to a lesser extent than other immunosuppressants. It is ahinese Medical Association. All rights reserved.
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expressed in activated lymphocytes. Its inhibitory effect on the
type II form of IMPDH is five-fold that for the type I isoform,
which is expressed in most cell types.7,8 However, there are
very few data on MMF treatment of skin manifestations in LE.
Skin diseases such as bullous pemphigoid, pemphigus, psori-
asis, and atopic dermatitis have been shown to improve
significantly with MMF treatment.9,10 MMF also seems to be a
successful approach for the treatment of therapy-resistant skin
lesions of subacute CLE.11 However, the role of MMF in CLE
therapy is yet to be clearly established.
Human SLE and its murine models, MRL/lpr or
NZB  NZW (NZBW) mice, are well known to be charac-
terized by a wide range of symptoms, such as glomerulone-
phritis, dermatitis, arthritis, and Ig deposition at the
dermaleepidermal junction (DEJ) of the skin.12
Desmoglein 3 (Dsg3), a major component of epidermal
desmosomes, was identified as a skin-specific autoantigen.
The anti-Dsg3 IgA was found to be most correlated with skin
disease aggravation.13 UVB exposure accelerates the devel-
opment of lesions and immune deposits, but does not accel-
erate systemic disease. Skin disease in murine lupus requires T
cells and, to a lesser extent, B cells but is independent of
antibody production. Long-term exposure to low-dose UVB
irradiation accelerated the development of skin lesions and
enhanced the intensity of the positive skin lupus band. The
contents of anti-DNA antibodies in sera, the incidence of
positive findings in skin lupus band test (LBT), and the extent
of glomerulonephritis were not influenced by the UVB
irradiation.14,15
Although MMF has been shown to have a beneficial effect
in preventing disease development in mice, the precise cellular
and molecular mechanism of its action is not completely
known, especially with regard to its role in the development of
skin inflammation. Herein, in order to gain insight into the
therapeutic effects of MMF, UVB-induced NZBW F1 mice
were treated with MMF and changes in cutaneous manifesta-
tions, histopathology, immunopathologic features, and labo-
ratory abnormalities were assessed.
2. Methods2.1. Animals and treatmentsThe experiments were conducted in accordance with the
U.S. National Institute of Health Guide for the Care and Use
of Laboratory Animals and the Animal Research Guidelines of
Taichung Veterans General Hospital (the Institutional Animal
Care and Use Committee Approval No: La-99738). Female
11-week-old NZBW F1 mice were purchased from the labo-
ratory animal center of National Taiwan University College of
Medicine and were assessed when they were aged 20 weeks,
when proteinuria and cutaneous lesion were present. Protein-
uria was assessed by determination of urine albumin using
reagent striped Albustix (Bayer, Spain) and was scored on a
0e4 scale: 0 indicates the absence of or trace levels of pro-
teinuria; 1 indicates proteinuria values of 0.30e1.00 g/L; 2indicates values of 1.0e3.0 g/L; 3 indicates values 3.0e10.0 g/
L; and 4 indicates values >10.0 g/L. After the mice were
sacrificed at Day 190, the serum was collected for examination
of blood urea nitrogen (BUN) and interleukin 6 (IL-6) levels.2.2. Ultraviolet light irradiation on the skinA sun lamp was used to emit mid-wave UV light ranging
from 290 nm to 315 nm (mainly UVB) with a peak at 305 nm,
and the energy output of a bank of three tubes was 2.4 mW/
cm2 at a distance of 15 cm measured using a UVR-305/365
UV-Radiometer (Toshiba Medical Supply, Tokyo, Japan).15
The two experimental groups (with or without MMF treat-
ment) comprised 20-week-old NZBW F1 mice. The dorsal
skin of the mice was shaved twice a week, and an irradiation
dose of 500 mJ/cm2 was administered every other day in a
photoirradiation cage, and each mouse received 28 doses in
total.2.3. MMF treatment of NZBW F1 miceThe beginning of UVB induction was Day 0. When cuta-
neous lesions were present in NZBW F1 mice at age 6 months
(Day 50), MMF (purchased from Roche Pharmaceuticals, Inc.,
Basel, Switzerland) was provided as a daily gavage at a dose
of 60 mg/kg. MMF was started at Day 50 and administered
until the experiment ended on Day 190.2.4. Dermal morphological examination and
histochemical stainingThe dorsal skin of the mice was fixed in neutralized 10%
formaldehyde solution. A routine pathologic examination of
the skin was performed and examined by hematoxylin and
eosin (H&E) staining. Optimal cutting temperature
compound-embedded skin was stored at 70 C until cryostat
sectioning at 5 mm thickness for immunofluorescence staining
and in situ zymography. The severity of skin inflammation was
examined by the sum of the involved skin area score and the
scorings for three items: inflammatory cell infiltration, edema
and scaling/hyperkeratosis in H&E staining.16,17 The degree of
each item was assessed as follows: 0 ¼ no symptoms;
1 ¼ light; 2 ¼ mild; 3 ¼ severe.17 The infiltrated inflammatory
cells were further compared by CD4 and CD8 cell counting on
an immunofluorescence graph.172.5. Identification of immunodeposition in skinThe LBTwas performed on the dorsal skin of the examined
mice.14 Briefly, 5 mm-thick (approximately) frozen sections
mounted on glass slides were dried and washed in phosphate-
buffered saline (PBS). The skin sections were reacted with
Texas red conjugated horse anti-mouse IgG (Vector) and
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse
IgM (Abcam, Cambridge, UK), and observed under a laser
confocal microscope (FV1000-D; Olympus, Tokyo, Japan).
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deposition of immune complexesdlaser confocal
microscopy imageryTo detect Dsg3 as a tissue-specific autoantigen in NZBW F1
mice, serial frozen sections of dermal tissues from these mice
were assessed by a specific goat anti-Dsg3 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and FITC-conjugated
horse anti-mouse IgG monoclonal antibody for immunofluo-
rescence double staining according to the manufacturer’s in-
structions. Nonspecific Ig binding sites were blocked with
normal bovine serum for 30 minutes at room temperature, and
then with goat anti-Dsg 3 polyclonal antibody with PBS-Triton
100 containing 5% nonfat milk. After incubation at 4 C over-
night, the dermal sections were washed with PBS and incubated
with rhodamine-conjugated donkey anti-goat IgG for 1 hour at
room temperature. Then, FITC-conjugated horse anti-mouse
IgG antibody was incubated for 1 hour at room temperature to
detect immunocomplex.After washingwith PBS andmounting,
the fluorescence was imaged using a laser confocal microscope
(FV1000-D).2.7. In situ zymographyTo detect the loci of extracellular matrix proteolytic activity
(MMPs activity) within frozen skin sections of onset andMMF-
treated animals, an in situ zymography approach was
employed.18,19 Briefly, 8 mm skin sections were washed in PBS
and incubated for 2 hours in DQ-labeled gelatin (Invitrogen,Fig. 1. (A) Survival rate, (B) proteinuria, (C) blood urea nitrogen, and (D) serum int
mofetil treatment. Day 0 was the time of UVB induction. Mycophenolate mofeti
*p < 0.05, **p < 0.01, ***p < 0.001 compared to the NZBW group.Carlsbad, CA, USA) substrate solution (20 mg/mL DQ-gelatin,
50 mM Tris pH 6.8, 50 mM NaCl, 20 mM CaCl2) at 37
C in
the dark. Substrate solution was washed off, slides were incu-
bated in 4% formaldehyde for 10 minutes, washed with PBS,
mounted with Dapi-Fluoromount-G (SouthernBiotech, Bir-
mingham,AL,USA), and photographedwith identical exposure
settings using a laser confocal microscope (FV1000-D).2.8. Gel zymographyThe frozen skin tissue was homogenized in Tris buffer
(50 mM Tris-HCl, pH 7.5, 150 mmol/l NaCl) and then
centrifuged, after which the supernatant was collected. The
protein content of supernatants was determined by preparing
BSA solution as the standard curve. A 20-mg sample of protein
from each tissue sample was run on 8.0% SDS-PAGE con-
taining gelatin (1.0 mg/mL) without previous heating or
reduction. After electrophoresis, gelatin-lytic bands were
identified by staining with Coomassie Brilliant Blue and the
images were analyzed with a 1-D Gel-Pro analyzer.2.9. Statistical analysisAll values are expressed as mean  standard deviation.
Parametric continuous data between different groups were
analyzed by KruskaleWallis nonparametric test. All statistical
analyses were conducted using the SPSS version 10.1 (SPSS
Inc., Chicago, IL, USA). A p value <0.05 (2-tailed) was
considered statistically significant.erleukin-6 level after UVB induction combined with or without mycophenolate
l treatment was added at Day 50 until the end of the experiment (Day 190).
618 Y.-F. Lee et al. / Journal of the Chinese Medical Association 76 (2013) 615e6233. Results3.1. Clinical findings and survival ratesProteinuria was raised from 1 to >2 in NZBW F1 mice at
age 17 weeks. UVB induction was initiated at age 20 weeksFig. 2. A representative histopathologic image of UVB-induced NZBW F1 mouse sk
induced NZBW F1 mice. (DeF) skin of UVB-induced NZBW F1 mice with MMF
field, bar ¼ 50 mm, hematoxylin and eosin staining. (C and F) CD4 (red) and CD
inflammation severity and graph counting of CD8 T cells were significantly attenuat
*p < 0.05 compared to the NZBW group.(Day 0) until the proteinuria was above 50%, and in the
NZBW F1 mice, the level of proteinuria was 2 plus. MMF
therapy was added at Day 50 when mild melanosis or
dermatitis was observed. After UVB induction (Day 105), the
first deaths among the NZBW F1 mice were noted (Fig. 1A).
Following MMF treatment, the survival rate of MMF groupin section after mycophenolate mofetil (MMF) treatment. (AeC) skin of UVB-
treatment. (A and D) low power field, bar ¼ 200 mm. (B and E) high power
8 (green) staining, bar ¼ 20 mm. (G) After quantification, the scores of skin
ed in the MMF-treated group ( p < 0.05), but CD4 T cells were not observable.
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Until the end of the experiment (Day 190), the survival rate of
UVB-induced NZBW F1 mice was significantly low (35.7%,
5/14) as compared with that in mice that received MMF
treatment (81.8%, 9/11; Fig. 1A, p < 0.05). In UVB-induced
NZBW F1 mice, 78.6% (11/14) had a proteinuria level >2.
The proteinuria was significantly improved in MMF-treated
NZBW F1 mice (Fig. 1B, p < 0.05). After sacrifice and col-
lecting serum for renal function assay (Day 190), the MMF
group showed a significant decrease in the serum BUN level
(Fig. 1C, p < 0.05) but no difference in creatinine level. The
concentrations of serum IL-6 in the NZBW and MMF groups
were 10.23  4.92 pg/mL (n ¼ 11) and 2.84  0.87 pg/mL
(n ¼ 14), respectively (Fig. 1D). After MMF treatment, the
serum IL-6 level was significantly reduced (Fig. 1D,
p < 0.001).3.2. Pathologic findings after MMF treatmentSubcutaneous edema and moderate infiltration of inflam-
matory cells were noted in NZBW lupus mice (Fig. 2A and B).
The infiltrated cells were lymphocytes (Fig. 2C). Mild
epithelial parakeratosis and homogenous substance deposition
in the derma were also present in NZBW lupus mice (Fig. 2B).
After MMF treatment, the epithelial parakeratosis andFig. 3. Immune complexes deposition in UVB-induced NZBW F1 mice. (A) UV
phenolate mofetil treatment. IgG and IgM staining were merged with DAPI st
maleepidermal junction. The IgG deposition was significantly attenuated after myco
found. *p < 0.05.homogeneous substance deposition in the dermis were atten-
uated (Fig. 2D and E). The scoring of the skin inflammation
severity revealed that MMF treatment significantly decreased
the severity of skin lesions (Fig. 2G, p < 0.05). The
lymphocyte results revealed that the infiltration of CD8 T cells
was also markedly attenuated in MMF-treated NZBW F1 mice
(Fig. 2F, green). However, the number of CD4 T cells was not
significantly affected in this local distribution (Fig. 2F, red).
The graph counting results in Fig. 2G show that infiltrated
CD8 T cells but not CD4 T cells were attenuated ( p < 0.05).3.3. Deposition of immune complexes in UVB-induced
NZBW F1 miceDeposition of immune complexes was identified using
immunofluorescence staining pattern with the antibody to IgG
and IgM showing evidence for immune complexes at the DEJ.
Both IgG and IgM deposition (deposition of immune com-
plexes) were conspicuous at the DEJ and dermis in UVB-
induced NZBW lupus mice (Fig. 3A). However, this pattern
appeared to be reduced in the skin of UVB-induced NZBW F1
mice with MMF treatment (Fig. 3B). Regarding the quantifi-
cation of lupus band (deposition of immune complexes at the
DEJ), there was a reduced tendency for the deposition of
immune complexes in the MMF-treated group (Fig. 3C). TheB-induced NZBW F1 mice. (B) UVB-induced NZBW F1 mice with myco-
aining. Bar ¼ 50 mm. (C) Quantitation of immune complexes at the der-
phenolate mofetil treatment ( p < 0.05), but no difference in IgM intensity was
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(Fig. 3C, p < 0.05), but IgM intensity was unchanged
(Fig. 3C, p > 0.05).3.4. Deposition of immune complexes colocalized with
Dsg3The immune complexes at the DEJ were represented by
anti-IgG staining (green color) in NZBW lupus mice (Fig. 4A)
and MMF-treated mice (Fig. 4B). After merging the Dsg3
protein staining (Fig. 4A and B, red color), the colocalized
image of IgG and Dsg3 showed significant staining (yellow
color) at the DEJ in NZBW lupus mice (Fig. 4A, merge),
whereas there was negligible staining in the MMF treatment
group (Fig. 4B, merge). This pattern was more clearly
apparent in the close-up images (Fig. 4C and D). The rate of
IgG colocalization with Dsg3 was significantly attenuated
after MMF treatment (Fig. 4E, p < 0.001).3.5. In situ zymographyUsing a fluorescently labeled gelatin substrate, frozen skin
sections were assayed for total gelatinase (MMPs) activity.
The major gelatinase activity occurred at the epithelial layer
(Fig. 5A). NZBW F1 skin showed a high-level of gelatinase
activity with a wide, thick band (Fig. 5A, top), and a similar
signal band was also detected in the skin section of MMF-
treated mice, but gelatinase activity was attenuated (Fig. 5A,
bottom). After quantification of gelatinase activity at the
epithelium, MMP intensity was significantly attenuated at the
epidermis and DEJ in the MMF group ( p < 0.001; Fig. 5B).3.6. Gelatin zymographyGelatinolytic activities of the skin samples were detected
by zymography (Fig. 5C). The gelatin-lytic bands at 92Fig. 4. Double staining of immune complexes deposition IgG and skin autoantigen
mice, (B and D) UVB-induced NZBW F1 mice with mycophenolate mofetil treatm
merged with DAPI counterstaining, bar ¼ 50 mm. (C and D) The close-up im
bar ¼ 10 mm. (E) The rate of colocalization was significantly attenuated after my(proMMP-9), 72 (proMMP-2), and 62 (MMP-2) kDa are
presented in Fig. 5C and their internal control protein (a-
tubulin) was also analyzed by Western blot (Fig. 5C).
Following MMF treatment, proMMP-2 and MMP-2 activity in
the skin was reduced and the intensity was significantly
attenuated in proMMP-2 (Fig. 5D, p < 0.05).
4. Discussion
CLE and its various clinical subtypes cause dermal
inflammation culminating in keratinocyte damage at the
DEJ.20 During the initiation phase, an autoimmune aberrant
response induces tissue injury. Environmental factors are
necessary to trigger the immune system, and these include UV
light. A systematic review of the recent literature on CLE
showed that mouse models, such as the MRL/lpr, NZBW, and
BSXB mouse strains, can be used to study the mechanisms
underlying the disease as well as therapeutic options. In NOD
mice, delayed clearance of apoptotic debris and high auto-
antibody production were found following repeated UV
irradiation.21
Recently, the mechanisms of UVB irradiation in auto-
inflammatory skin disease have been extensively revealed. IL-
6 stimulates B cell differentiation, directly inducing the IgG
anti-DNA antibodies secretion, and promotes the differentia-
tion of cytotoxic T cells. SLE patients release IL-6 in response
to UVA or UVB irradiation possibly contributing to the flare-
up of skin lesions.22 In this study, a raised IL-6 level was also
found in NZBW mice, and MMF treatment significantly
reduced the IL-6 level (Fig. 1D, p < 0.001). Other cytokines,
colony-stimulating factor 1, IFN-related proteins and high
mobility group box protein 1 were also correlated with the
disease progression in the sera of MRL/lpr mice or
humans.23e25
The incidence of IgG deposition at the DEJ of MRL/lpr
mice increases with age and reaches more than 80% after ageDsg3 in UVB-induced NZBW F1 mice. (A and C) UVB-induced NZBW F1
ent. The individual image of IgG staining (green) and Dsg3 staining (red) were
age indicates that the IgG colocalized with the autoantigen Dsg3 (yellow),
cophenolate mofetil treatment ( p < 0.001). ***p < 0.001.
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Ig deposition at the DEJ, indicating that skin-specific auto-
antigen or/and autoantibodies play a role in exacerbating or
amplifying the manifestation of skin disease.13 Therefore, we
performed this study when mice had reached age 20 weeks
and there was evidence of systemic lupus onset, such as the
presence of proteinuria. Skin membrane structures are able to
bind chromatineIgG complexes, and upregulated expression
of structures in skin membranes may increase the binding
capacity of such immune complexes. Reduced expression
would eventually be beneficial for the organs in which depo-
sition occurs.6 In this study, we established a UVB-induced
NZBW lupus mouse model and identified cutaneous
lesions, including skin inflammation with CD4 and CD8
lymphocytic infiltration (Fig. 2AeC). MMF treatment was
significantly beneficial for decreasing IgG immune complexes
deposition (Fig. 3). The intensity of IgG immune complex
deposition, considered a chronic immune globulin, at the DEJ
was significantly attenuated in the MMF group (Fig. 3C,
p < 0.05).
The use of typical treatments, such as steroids with sys-
temic treatment, usually provides additional benefit. Never-
theless, many patients suffer from treatment side effects and
cutaneous lesions that are resistant to therapy. There is a need
therefore for alternative therapies. MMF is a selective andFig. 5. In situ and gel zymography assay of matrix metalloprotease (MMP) activity
mycophenolate mofetil-treated mice are shown (bar ¼ 200 mm). (B) After quantifica
group ( p < 0.001). (C) Gel zymography shows conspicuous gelatin-lytic bands
tubulin) was also analyzed by Western blot. (D) There was reduced proMMP-2 and
( p < 0.05). *p < 0.05, ***p < 0.001, #p ¼ 0.052.potent immunosuppressive agent and affects the gonadal or-
gans to a far lesser degree than other immunosuppressants.
Dsg3 was identified as an autoantigen in a human skin
autoimmune disease, which was first discovered in bullous
pemphigus vulgaris, in which Dsg3 is present microscopically
in the suprabasal layer of the epidermis. Dsg3 possesses
pathogenic properties and its presence results in the produc-
tion of autoantibodies. Although an association has been
reported in the MRL/lpr mouse model,13 it has not been pre-
viously described in CLE patients27 or in the NZBW mouse
model. In this study, deposition of immune complexes (IgG)
was observed in significant amounts and it was found that they
had colocalized with the autoantigen Dsg3 at the basal layer
and even between the spinous layers of the skin in NZBW
lupus mice (Fig. 4A and C), but this was not shown in NZBW
lupus mice with MMF treatment (Fig. 4B and D). This
demonstrates that strong associations exist among autoanti-
body (IgG) deposition, Dsg3 exposure, and severity in the
NZBW model. However, skin inflammation in the murine
models exhibit some histological dissimilarity compared with
that in models of skin lesions in human SLE. Therefore,
whether or not human SLE patients develop anti-Dsg3 coun-
terparts in these murine models requires further study.
Hedberg et al6 revealed that upregulated intradermal MMP
activity may be crucial for the deposition of immunein the skin. (A) Representative figures of in situ zymography in NZBW F1 and
tion, MMP intensity was significantly attenuated in the mycophenolate mofetil
(proMMP-9, proMMP-2, and MMP-2), and their internal control protein (a-
MMP-2 activity and the intensity was significantly attenuated for proMMP-2
622 Y.-F. Lee et al. / Journal of the Chinese Medical Association 76 (2013) 615e623complexes in the skin of lupus-prone mice, and showed that
dermal MMP-2 and MMP-9 increase CLE disease progres-
sion. We also found a high level of local gelatinase activity in
NZBW F1 skin (Fig. 5A). MMP intensity was significantly
attenuated at the epidermal and DEJ in the MMF group
(Fig. 5B). The results also showed that proMMP-2 activity was
significantly reduced in the whole skin sample by gelatin
zymography (Fig. 5 C and D).
T cells have been found to be prominent within lesions of
CLE.28 Cytotoxic skin-homing CD8þ T cells in particular are
conspicuous within the scarring lesions of discoid CLE and
may be sufficient to initiate lupus-like autoimmunity.28,29
Furthermore, T cells may act at multiple stages in lupus,
including modulation of B cells to secrete autoantibodies, and
regulation of the activity of effector cells, such as macro-
phages and NK cells.30 MMF can induce apoptosis of acti-
vated lymphocytes, thereby eliminating cells responding to
antigenic stimulation and subsequently decreasing the
recruitment of lymphocytes and monocytes into sites of
inflammation.7,8 In this study, we observed that the recruit-
ment of CD8 lymphocytes in the subcutaneous site was
significantly reduced after MMF treatment (Fig. 2F and G).
This change may indirectly attenuate antigenic stimulation,
such as autoantibody to Dsg3 (Fig. 4). The results revealed
that the LBT was indeed attenuated (Figs. 3 and 4), and thus
we speculate that the B cell function was inhibited after MMF
treatment.
In conclusion, MMF was greatly beneficial in the treatment
of cutaneous lupus erythematosus (CLE) in NZBW F1 mice
through the inhibition of proliferative responses of T lym-
phocytes as well as B lymphocytes, which implies that levels
of antibodies were dramatically diminished. However, activity
of MMPs was associated with the severity of CLE, so further
study is needed to confirm its potential clinical value for CLE
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